HCM
NUVB icon

Highbridge Capital Management’s Nuvation Bio NUVB Stock Holding History

Highbridge Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-357,761
Closed -$4.19M – 180
2020
Q4 		$4.19M Buy
+357,761
New +$3.72M 0.16% 89

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Highbridge Capital Management's NUVB Position: Q1 2021 in Review

Highbridge Capital Management sold out of Nuvation Bio (NUVB) in Q1 2021, closing a stake of 357,761 shares — an estimated $4.19M sold.

Highbridge Capital Management first reported a position in NUVB in Q4 2020 and held it in 1 quarter. The position peaked at $4.19M in Q4 2020. 73 funds tracked by Wall St. Rank hold NUVB as of Q1 2021.

  • Highbridge Capital Management reported no remaining Nuvation Bio position as of Q1 2021 after selling out during the quarter.
  • Highbridge Capital Management sold 357,761 Nuvation Bio shares in Q1 2021, an estimated $4.19M.
  • Highbridge Capital Management first reported a position in Nuvation Bio in Q4 2020 and held it in 1 quarter.
  • Highbridge Capital Management's Nuvation Bio position peaked at $4.19M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2021.

Based on Highbridge Capital Management's 13F filing for Q1 2021, filed 12 May 2021.